SRNE, US83587F2020

Sorrento appeal is dismissed before the November 6 report for Sorrento Therapeutics stock

Published on 10/16/2026 at 00:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A Texas docket entered the dismissal on September 29, 2026. The next Sorrento Therapeutics stock report is November 6, with 543.71 million shares outstanding.

Legal timeline and market scale

A Texas docket entered a voluntary dismissal on September 29, 2026.
The next earnings report is scheduled for November 6, 2026.
Sorrento carried a USD 108,740.00 market value and a 543.71 million share count on October 15, 2026.

SRNE, US83587F2020, Illustration mit AI erstellt.

Sorrento appeal is dismissed before the November 6 report for Sorrento Therapeutics stock, with the latest market snapshot showing 543.71 million shares outstanding. Law360 reported that a voluntary dismissal was entered in the Texas bankruptcy appeal on September 29, 2026.

What did the appeal decision change?

The docket entry closed an individual appeal filed in the Sorrento bankruptcy proceedings. A separate legal review published by JD Supra described a June 21, 2026 bankruptcy-court ruling that upheld a gatekeeping provision and assigned certain claims to a liquidation trust. The legal timeline therefore remains central to the company story.

Three dates define the case

On June 21, 2026, the bankruptcy court ruled on the gatekeeping provision, according to JD Supra. On September 18, 2026, a clerk notice recorded the filing of an appeal. On September 29, 2026, the docket recorded the voluntary dismissal, according to Law360.

When are the next company dates?

Investing.com lists November 6, 2026 as the next earnings report date. MarketWatch also lists March 3, 2027 for a 2023 earnings report, giving investors two dated reference points for the company calendar.

Market value remains limited

As of October 15, 2026, Sorrento was last at USD 0.0002 on the OTC Markets, while its 52-week range was USD 0.0001 to USD 0.0160. The same source listed a market capitalization of USD 108,740.00 and revenue of USD 64.27 million, although it did not identify a reporting period for that revenue figure. Sorrento's biotechnology operations and bankruptcy history make the legal timeline and the November reporting date more relevant than a conventional growth comparison.